Targeting NTCP for liver disease treatment: A promising strategy  

作　　者：Xin Tan Yu Xiang Jianyou Shi Lu Chen Dongke Yu 

机构地区：[1]Department of Pharmacy,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu,610072,China [2]Personalized Drug Therapy Key Laboratory of Sichuan Province,School of Medicine,University of Electronic Science and Technology of China,Chengdu,610072,China [3]College of Medicine,University of Electronic Science and Technology,Chengdu,610072,China [4]Guanghan People's Hospital,Guanghan,Sichuan,618300,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第9期1267-1281,共15页药物分析学报（英文版）

基　　金：funded by Research Project of Sichuan Provincial Health Commission,China(Grant No.:21PJ071).

摘　　要：The sodium taurocholate co-transporting polypeptide (NTCP), a bile acids transporter, has been identified as a new therapeutic target for the treatment of liver disease. This paper thoroughly investigates the function of NTCP for regulating bile acid regulation, its correlation with hepatitis B and D infections, and its association with various liver diseases. Additionally, in this review we examine recent breakthroughs in creating NTCP inhibitors and their prospective applications in liver disease treatment. While this review emphasizes the promising potential of targeting NTCP, it concurrently underscores the need for broader and more detailed research to fully understand the long-term implications and potential side effects associated with NTCP inhibition.

关 键 词：NTCP Bile acids metabolism NTCP inhibitor Viral hepatitis 

分 类 号：R575[医药卫生—消化系统]